

Monaco

Population 2016

<1 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0 (0–0)	0 (0–0)
Mortality (HIV+TB only)	0 (0–0)	0 (0–0)
Incidence (includes HIV+TB)	0 (0–0)	0 (0–0)
Incidence (HIV+TB only)		
Incidence (MDR/RR-TB)**	0 (0–0)	0 (0–0)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0 (–)	0 (–)	0 (–)
Males	0 (–)	0 (–)	0 (–)
Total	0 (–)	0 (–)	0 (0–0)

TB case notifications, 2016	
Total cases notified	
Total new and relapse	
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	
- % pulmonary	
- % bacteriologically confirmed among pulmonary	

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	null

TB/HIV care in new and relapse TB patients, 2016		Number	(%)
Patients with known HIV-status who are HIV-positive			
- on antiretroviral therapy			

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			(–)
Estimated % of TB cases with MDR/RR-TB	2.4% (1.6–3.2)	11% (9.1–14)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: , XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB:	

Treatment success rate and cohort size		
	Success	Cohort
New cases registered in 2015		
Previously treated cases registered in 2015		
HIV-positive TB cases registered in 2015		
MDR/RR-TB cases started on second-line treatment in 2014		
XDR-TB cases started on second-line treatment in 2014		

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017	
National TB budget (US\$ millions)	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New cases

— Previously treated cases

— HIV-positive

— MDR/RR-TB

— XDR-TB